Abstract
BackgroundThe relationship between statin use and the risk of ovarian or endometrial cancer remains controversial. Here, we investigated the relationship between statin use and the risk of ovarian and endometrial cancers.MethodsWe conducted a meta-analysis using articles retrieved from the PubMed, Embase, and Web of Science databases. All original comparative studies published in English that were related to statin use and the risk of ovarian or endometrial cancer were included.ResultsThis meta-analysis included 19 studies enrolling 1,999,362 female subjects and 19,849 cancer cases (7,948 ovarian cancer cases and 11,901 endometrial cancer cases). The overall analysis indicated that statin use did not significantly reduce the risk of ovarian cancer [relative risk (RR) = 0.88, 95% confidence interval (CI) 0.76–1.03, p = 0.12] or the risk of endometrial cancer (RR = 0.88, 95% CI 0.78–1.00, p = 0.05.) Subgroup analyses based on study type, percentage of cancer cases, study location, and quality of studies also supported our conclusions. No association was found between long-term statin use (> 5 years) and the risk of ovarian cancer (RR = 0.73, 95% CI 0.51–1.04, p = 0.08) or endometrial cancer (RR = 0.79, 95% CI 0.58–1.08, p = 0.14).ConclusionsStatin use did not lower the risk of ovarian cancer or endometrial cancer. The long-term use of statins (> 5 years) was not associated with a reduction in the risk of ovarian or endometrial cancer.
Highlights
The relationship between statin use and the risk of ovarian or endometrial cancer remains controversial
Two Randomized control trial (RCT), six cohort studies and 11 case-control studies were included, and there was no significant association between the use of statins and the risk of ovarian or endometrial cancer based on study type
Subgroup analyses based on the quality of studies indicated that no significant association between statin use and the risk of endometrial cancer was observed in studies of high quality or low quality
Summary
The relationship between statin use and the risk of ovarian or endometrial cancer remains controversial. We investigated the relationship between statin use and the risk of ovarian and endometrial cancers. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) are cholesterol-lowering drugs that are primarily used for hypercholesterolemia therapy They have antitumor effects, which have been reported in experimental research on many cancers [5]. A recent population-based study of 161,808 postmenopausal women indicated that statin use can reduce the risk of endometrial cancer but not that of ovarian cancer [12]. Another study reported that statin use reduced the risk of ovarian cancer [13]. Previous studies have reported that statin use was associated with a reduced risk of ovarian or endometrial cancer [14, 15]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
